| Rebecca J Hafner-fogarty, MD | |
|
33491 135th Ave, Avon, MN 56310-9617 | |
| (320) 356-1019 | |
| Not Available |
| Full Name | Rebecca J Hafner-fogarty |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 33491 135th Ave, Avon, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497783963 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25004 (Minnesota) | Primary |
| Entity Name | Centracare Health System - Long Prairie |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1164471678 PECOS PAC ID: 3870524598 Enrollment ID: O20061104000579 |
News Archive
Charles River Laboratories International, Inc. today reported its results for the second quarter of 2010. For the quarter, net sales were $292.1 million, a decline of 5.2% from $308.2 million in the second quarter of 2009. Foreign currency translation reduced the sales growth rate by 0.1%. A modest sales increase in the Research Models and Services segment was offset by lower sales for the Preclinical Services segment.
Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.
First produced only in the past decade, human induced pluripotent stem cells are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases-and eventually in treating them.
Research One, Inc., an affiliate of Orlando Heart Specialists (OHS), is seeking candidates for a clinical drug trial that could reduce cholesterol levels with just one injection, twice a month.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca J Hafner-fogarty, MD 33491 135th Ave, Avon, MN 56310-9617 Ph: (320) 356-1019 | Rebecca J Hafner-fogarty, MD 33491 135th Ave, Avon, MN 56310-9617 Ph: (320) 356-1019 |
News Archive
Charles River Laboratories International, Inc. today reported its results for the second quarter of 2010. For the quarter, net sales were $292.1 million, a decline of 5.2% from $308.2 million in the second quarter of 2009. Foreign currency translation reduced the sales growth rate by 0.1%. A modest sales increase in the Research Models and Services segment was offset by lower sales for the Preclinical Services segment.
Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.
First produced only in the past decade, human induced pluripotent stem cells are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases-and eventually in treating them.
Research One, Inc., an affiliate of Orlando Heart Specialists (OHS), is seeking candidates for a clinical drug trial that could reduce cholesterol levels with just one injection, twice a month.
› Verified 9 days ago